
    
      Eligible patients for this study must have a diagnosis of probable AD and must have
      clinically meaningful agitation secondary to AD.

      This is a multicenter, randomized, double-dummy, double-blind, placebo-controlled study,
      consisting of 10 weeks of treatment.

      Up to 200 patients will be enrolled at approximately 30-40 centers in the US.

      Study medication will be administered orally twice-daily from Day 1 through Day 70. Screening
      must occur within within approximately 4 weeks prior to randomization. Following screening
      procedures for assessment of inclusion and exclusion criteria, eligible patients will be
      randomized into the study.
    
  